Mayo Clinic Translational Polycystic Kidney Disease Center

Rochester, Minnesota, United States

Mayo Clinic Translational Polycystic Kidney Disease Center

Rochester, Minnesota, United States
SEARCH FILTERS
Time filter
Source Type

Holditch S.J.,Mayo Medical School | Schreiber C.A.,Mayo Medical School | Harris P.C.,Mayo Clinic Translational Polycystic Kidney Disease Center | LaRusso N.F.,Mayo Medical School | And 4 more authors.
Kidney International | Year: 2016

Polycystic kidney disease (PKD) involves progressive hepatorenal cyst expansion and fibrosis, frequently leading to end-stage renal disease. Increased vasopressin and cAMP signaling, dysregulated calcium homeostasis, and hypertension play major roles in PKD progression. The guanylyl cyclase A agonist, B-type natriuretic peptide (BNP), stimulates cGMP and shows anti-fibrotic, anti-hypertensive, and vasopressin-suppressive effects, potentially counteracting PKD pathogenesis. Here, we assessed the impacts of guanylyl cyclase A activation on PKD progression in a rat model of PKD. Sustained BNP production significantly reduced kidney weight, renal cystic indexes and fibrosis, in concert with suppressed hepatic cystogenesis in vivo. In vitro, BNP decreased cystic epithelial cell proliferation, suppressed fibrotic gene expression, and increased intracellular calcium. Together, our data demonstrate multifaceted effects of sustained activation of guanylyl cyclase A on polycystic kidney and liver disease. Thus, targeting the guanylyl cyclase A-cGMP axis may provide a novel therapeutic strategy for hepatorenal fibrocystic diseases. © 2017 International Society of Nephrology.

Loading Mayo Clinic Translational Polycystic Kidney Disease Center collaborators
Loading Mayo Clinic Translational Polycystic Kidney Disease Center collaborators